



Attn: Trading and Market Making/Legal and Compliance/Operations/Systems
UNIFORM PRACTICE ADVISORY (UPC #12-21) 02/08/2021
TriVascular Sales LLC (n/k/a Endologix, Inc) (ELGXQ)

Notice has been received that the above Company's Third Amended Joint Plan of Reorganization became effective on 10/01/2020. Existing Equity Interests On the Effective Date, all Existing Equity Interests in the Debtors, and claims arising therefrom or related thereto, shall be cancelled, released and extinguished, and Holders of such Existing Equity Interests will receive no distribution under the Plan. Please consult the Company's Third Amended Joint Plan of Reorganization for further details.¹

Members are reminded of their obligations under FINRA Rule 2111 if they continue to engage in transactions in the above security after the effective date.

Pursuant to FINRA Rule 11530, members are advised that, among other things, in contracts for securities where a public announcement or publication of general circulation discloses that the securities have been deemed worthless, deliveries shall consist a) the worthless securities or; or b) a Letter of Indemnity which shall grant the purchaser any rights and privileges which might accrue to the holders of the physical securities. Such deliveries shall operate to close-out the contract and shall be settled at the existing contract price pursuant to FINRA Rule 11530.

Questions regarding this notice should be directed to: FINRA Operations- 1-866-776-0800.

¹ See e.g., *In re: TriVascular Sales LLC, et al.*, Debtor. Chapter 11 Case No. 20-31840 (SGJ) Third Amended Joint Plan of Reorganization.